Medical professionals can use an MRI to examine the structure and function of your liver. MRIs are highly accurate and don’t use radiation. However, they can be expensive and not everyone is a ...

Please provide your email address to receive an email when new articles are posted on . Treatment responders demonstrated significant reductions in iron corrected T1 and liver fat content. Optimal ...

Adding MRI to CT may improve the accuracy of detecting nonviable disappearing liver metastases than CT alone among patients with initially unresectable colorectal liver metastases. However, confirmed ...

WASHINGTON & OXFORD, England--(BUSINESS WIRE)--Perspectum announced two research studies that were recently published, bringing hope to people with metabolic dysfunction-associated steatohepatitis ...

This prospective study included 135 patients (median age, 67 years; 66 women) who underwent MRI-guided SBRT for liver metastases across seven international centres between April 2019 and April 2023.

Non-alcoholic fatty liver disease (NAFLD) is the term for a range of conditions caused by a build‑up of fat in the liver. NAFLD develops in 4 stages: simple fatty liver (steatosis): a largely harmless ...

Quibim, a global company pioneering imaging biomarkers for precision medicine, is today announcing the launch of a new product, QP-Liver, which improves the diagnosis of diffuse liver diseases through ...

CHICAGO--(BUSINESS WIRE)--Contrast-enhanced ultrasound (CEUS) is more accurate and reliable than MRI for examining certain liver and kidney nodules, according to two new studies published in the ...

Researchers have developed a novel approach to treat liver tumors using magnet-guided microrobots in an MRI device. Canadian researchers led by Montreal radiologist Gilles Soulez have developed a ...

Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ENDRA Life Sciences Inc ...

The crossover of the bevacizumab and panitumumab survival curves in the PARADIGM study: A clue to time-related effects of bevacizumab on the risk of tumor progression. Risk of peritoneal recurrence ...